Other substances

PYR-41

A ubiquitin-activating enzyme E1 inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

PYR-41 is an experimental drug, which acts as a ubiquitin-activating enzyme E1 inhibitor. It was shown to reduce tissue damage associated with systemic inflammation (resulting from sepsis) in mice (Matsuo et al., 2018).

PYR-41 on PubChem

Synonyms

PYR 41

 

Structure image - PYR-41

CCOC(=O)C1=CC=C(C=C1)N2C(=O)/C(=C\C3=CC=C(O3)[N+](=O)[O-])/C(=O)N2

Supporting references

Link Tested on Impact factor Notes Publication date
A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
3CLpro Enzyme assay In vitro In silico Screening 		in silico; in vitro enzyme assay 2.74

Inhibited the SARS-CoV-2 3C-like protease in vitro with IC50 of ca. 17.38 μM.

 Feb/01/2021
Export (.csv)